Clinuvel Pharmaceuticals Limited (CLVLF)
USD 7.45
(0.0%)
USD 7.45
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 56.27 Million AUD | 13.55% |
| 2023 | 49.56 Million AUD | 32.68% |
| 2022 | 37.35 Million AUD | 32.49% |
| 2021 | 28.19 Million AUD | 107.45% |
| 2020 | 13.58 Million AUD | -25.94% |
| 2019 | 18.35 Million AUD | 50.51% |
| 2018 | 12.25 Million AUD | 80.52% |
| 2017 | 6.85 Million AUD | 262.4% |
| 2016 | -4.15 Million AUD | 62.98% |
| 2015 | -11.23 Million AUD | -78.51% |
| 2014 | -6.29 Million AUD | 23.47% |
| 2013 | -8.22 Million AUD | 19.73% |
| 2012 | -10.24 Million AUD | 18.95% |
| 2011 | -12.63 Million AUD | 19.3% |
| 2010 | -15.66 Million AUD | 9.79% |
| 2009 | -17.36 Million AUD | 3.59% |
| 2008 | -18 Million AUD | -75.72% |
| 2007 | -10.36 Million AUD | -17.0% |
| 2006 | -9.98 Million AUD | 23.88% |
| 2005 | -11.5 Million AUD | -44.82% |
| 2004 | -7.94 Million AUD | -93.16% |
| 2003 | -4.11 Million AUD | -22.38% |
| 2002 | -3.36 Million AUD | -45.81% |
| 2001 | -1.18 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 32.78 Million AUD | 0.0% |
| 2024 FY | - AUD | 13.55% |
| 2024 Q1 | 7.23 Million AUD | -51.58% |
| 2024 Q2 | 11.9 Million AUD | 0.0% |
| 2023 Q2 | 13.35 Million AUD | 82.51% |
| 2023 FY | - AUD | 32.68% |
| 2023 Q1 | 7.31 Million AUD | -70.72% |
| 2023 Q3 | 14.94 Million AUD | 11.9% |
| 2023 Q4 | 28.34 Million AUD | 89.66% |
| 2022 Q1 | 4.94 Million AUD | -54.44% |
| 2022 FY | - AUD | 32.49% |
| 2022 Q4 | 24.99 Million AUD | 91.7% |
| 2022 Q3 | 13.03 Million AUD | 47.81% |
| 2022 Q2 | 8.82 Million AUD | 78.22% |
| 2021 Q2 | 3.66 Million AUD | -0.0% |
| 2021 Q4 | 10.86 Million AUD | 0.0% |
| 2021 Q3 | 10.86 Million AUD | 196.09% |
| 2021 Q1 | 3.66 Million AUD | -36.41% |
| 2021 FY | - AUD | 107.45% |
| 2020 Q4 | 5.77 Million AUD | 0.32% |
| 2020 FY | - AUD | -25.94% |
| 2020 Q1 | 419.12 Thousand AUD | -93.76% |
| 2020 Q2 | 419.12 Thousand AUD | -0.0% |
| 2020 Q3 | 5.75 Million AUD | 1272.38% |
| 2019 Q2 | 1.66 Million AUD | -0.0% |
| 2019 Q3 | 6.7 Million AUD | 303.97% |
| 2019 FY | - AUD | 50.51% |
| 2019 Q1 | 1.66 Million AUD | -69.97% |
| 2019 Q4 | 6.71 Million AUD | 0.17% |
| 2018 Q3 | 5.53 Million AUD | 818.64% |
| 2018 Q4 | 5.52 Million AUD | -0.04% |
| 2018 Q2 | 602.15 Thousand AUD | -0.0% |
| 2018 FY | - AUD | 80.52% |
| 2018 Q1 | 602.16 Thousand AUD | -72.22% |
| 2017 Q2 | 1.25 Million AUD | 0.0% |
| 2017 Q1 | 1.25 Million AUD | 3049.04% |
| 2017 Q4 | 2.16 Million AUD | 0.32% |
| 2017 FY | - AUD | 262.4% |
| 2017 Q3 | 2.16 Million AUD | 72.58% |
| 2016 Q1 | -1.71 Million AUD | -8.84% |
| 2016 FY | - AUD | 62.98% |
| 2016 Q4 | -42.45 Thousand AUD | -0.6% |
| 2016 Q3 | -42.19 Thousand AUD | 97.55% |
| 2016 Q2 | -1.71 Million AUD | 0.0% |
| 2015 Q2 | -3.81 Million AUD | 0.0% |
| 2015 Q3 | -1.57 Million AUD | 58.69% |
| 2015 FY | - AUD | -78.51% |
| 2015 Q4 | -1.57 Million AUD | -0.17% |
| 2015 Q1 | -3.81 Million AUD | -220.16% |
| 2014 FY | - AUD | 23.47% |
| 2014 Q4 | -1.19 Million AUD | -0.43% |
| 2014 Q1 | -1.69 Million AUD | -25.52% |
| 2014 Q2 | -1.69 Million AUD | 0.0% |
| 2014 Q3 | -1.18 Million AUD | 30.1% |
| 2013 FY | - AUD | 19.73% |
| 2013 Q3 | -1.35 Million AUD | 0.0% |
| 2013 Q4 | -1.35 Million AUD | -0.08% |
| 2012 FY | - AUD | 18.95% |
| 2011 FY | - AUD | 19.3% |
| 2010 FY | - AUD | 9.79% |
| 2009 FY | - AUD | 3.59% |
| 2008 FY | - AUD | -75.72% |
| 2007 FY | - AUD | -17.0% |
| 2006 FY | - AUD | 23.88% |
| 2005 FY | - AUD | -44.82% |
| 2004 FY | - AUD | -93.16% |
| 2003 FY | - AUD | -22.38% |
| 2002 FY | - AUD | -45.81% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 40.157% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 8998.65% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -10569.715% |
| Qrons Inc. | -40.08 Thousand USD | 140504.671% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 6106.26% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 423.982% |
| BioStem Technologies, Inc. | -7.55 Million USD | 845.012% |
| Skye Bioscience, Inc. | -13.54 Million USD | 515.393% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 15424.722% |
| Rebus Holdings, Inc. | -951 Thousand USD | 6017.518% |
| CSL Limited | 4.78 Billion USD | 98.825% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 201.692% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 3315.75% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 454.61% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 1548.789% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 179.221% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 1049.173% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 23631.506% |
| SQZ Biotechnologies Company | -64.14 Million USD | 187.737% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 2228.066% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 3763.659% |
| Mesoblast Limited | -62.38 Million USD | 190.2% |
| Marizyme, Inc. | -34.28 Million USD | 264.157% |
| Genus plc | 73.7 Million USD | 23.642% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 951.175% |
| Pharming Group N.V. | 9.87 Million USD | -469.764% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 3883.457% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 1686.57% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 741.537% |
| ContraFect Corporation | -64.99 Million USD | 186.579% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 1343.331% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 4114.501% |
| IMV Inc. | -35.52 Million USD | 258.418% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 2521.685% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 10963.05% |
| ONE Bio Corp. | 13.61 Million USD | -313.395% |
| Accustem Sciences Inc. | -3.74 Million USD | 1602.117% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 216.689% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 4541.179% |
| Q BioMed Inc. | -617.62 Thousand USD | 9211.568% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -1475.465% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 2563.378% |
| Biomind Labs Inc. | -1.03 Million USD | 5539.626% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 241.978% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 2045.686% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 885.832% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -836836.288% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 225202.384% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 2349.259% |
| GB Sciences, Inc. | -1.41 Million USD | 4063.391% |
| Alpha Cognition Inc. | -9.7 Million USD | 679.826% |
| HST Global, Inc. | -5303.00 USD | 1061303.017% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 2835.809% |
| Halberd Corporation | -74.27 Thousand USD | 75862.458% |
| Enzolytics Inc. | -2.12 Million USD | 2751.971% |
| Agentix Corp. | -1.37 Million USD | 4202.449% |
| Resverlogix Corp. | -11.74 Million USD | 579.268% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 1937.261% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -216.02 Million USD | 126.051% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -4524.125% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -535.609% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 3854.445% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -14754.556% |
| AVAX Technologies, Inc. | -6.11 Million USD | 1020.643% |
| Zenith Capital Corp. | -8.6 Million USD | 753.911% |
| Genscript Biotech Corporation | -248.71 Million USD | 122.626% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 323133.098% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 2400.286% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 32070.345% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 3029.631% |
| Kadimastem Ltd | -2.62 Million USD | 2244.338% |
| Helix BioMedix, Inc. | -1.04 Million USD | 5478.472% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 31176.381% |
| LadRx Corporation | 412.28 Thousand USD | -13549.749% |
| Cell Source, Inc. | -4.27 Million USD | 1417.15% |
| Regen BioPharma, Inc. | 1.46 Million USD | -3738.833% |
| NovAccess Global Inc. | -1.03 Million USD | 5538.322% |
| Affymax, Inc. | -14.29 Million USD | 493.673% |
| Itoco Inc. | -1.86 Million USD | 3111.008% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 14924.192% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 5142.616% |
| Mobile Lads Corp. | -2.24 Million USD | 2611.004% |
| CytoDyn Inc. | -18.02 Million USD | 412.139% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 71308.792% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 460281.503% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 11687.018% |
| SYBLEU INC | -141.57 Thousand USD | 39850.794% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 5398.97% |
| International Stem Cell Corporation | 202 Thousand USD | -27759.206% |
| Bioxytran, Inc. | -3.82 Million USD | 1573.126% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 107006.527% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 2385.831% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 256.892% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 125156.88% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 2155.354% |
| Neutra Corp. | -181.24 Thousand USD | 31149.119% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 379.159% |
| PureTech Health plc | -11.62 Million USD | 584.008% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 379.178% |
| IXICO plc | -707 Thousand USD | 8059.773% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 832.278% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 216.402% |
| CSL Limited | 4.73 Billion USD | 98.811% |
| Cellectis S.A. | -92.63 Million USD | 160.749% |